Figure 5: Therapeutic effect of MePS2-1 siGRAMD1B in vitro and in vivo. | Nature Communications

Figure 5: Therapeutic effect of MePS2-1 siGRAMD1B in vitro and in vivo.

From: 2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity

Figure 5

(a) Knockdown of GRAMD1B using UM and MePS2-1-modified siRNAs (40 nM, 10% FBS-containing media) (n=1). (b) Intracellular binding of UM and MePS2-1 siGRAMD1B to Ago2 in HeyA8-MDR cells (50 nM, serum-free condition). (c) Effect of MePS2-1 siGRAMD1B on tumoral response to paclitaxel treatment in HeyA8-MDR orthotopic OvCa mouse model. (d) Knockdown of GRMAD1B by MePS2-1-siGRAMD1B-DOPC in HeyA8-MDR tumours. (e) Caspase 3 activity in tumours treated with MePS2-1-siCon-DOPC or MePS2-1-siGRAMD1B-DOPC +/− paclitaxel. Scale bar, 100 μm. (f) Effect of MePS2-1 siGRAMD1B on tumoral response to paclitaxel treatment in SKOV3-TR orthotopic OvCa mouse model. (P-values obtained with Student’s t-test; (b) ***P<0.001, compared with UM siGRAMD1B (n=3); (c,f) *P<0.05 or **P<0.01, compared with the corresponding control groups (n=10); (d) **P<0.01, compared with MePS2-1-siCon-DOPC group (n=2–3); (e), ****P<0.0001, compared with paclitaxel or MePS2-1-siGRAMD1B-DOPC monotherapy groups (n=10); bars and error bars represent mean values and the corresponding s.e.m. values).

Back to article page